Entities / Company
Xilio Therapeutics (United States).
organization
- Reports this week
- 0
- Active events
- 1
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
Scott Young has been appointed Vice President, Investor Relations at Xilio Therapeutics.Speculative1 report
-
Xilio Therapeutics granted options under Nasdaq Listing Rule 5635(c)(4) on August 2, 2025.Some support1 report
-
Xilio Therapeutics is advancing its drug candidate XTX301 in partnership with Gilead Sciences.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Scott Young Structural
Scott Young serves as Vice President of Investor Relations for Xilio Therapeutics.
History
Events by the month they beganJune 2026
4 events- Xilio Therapeutics shares underperformed the S&P 500 so far this year, based on events of August 14, 2025.
- Scott Young has been appointed Vice President, Investor Relations at Xilio Therapeutics.
- Xilio Therapeutics granted options under Nasdaq Listing Rule 5635(c)(4) on August 2, 2025.
- Xilio Therapeutics is advancing its drug candidate XTX301 in partnership with Gilead Sciences.